M. J. Mihatsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
M. J. Mihatsch has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
F Gudat
12 shared publicationsG Thiel
6 shared publicationsK Morozumi
5 shared publicationsM Kyo
5 shared publicationsB Ryffel
3 shared publicationsF. Gudat
3 shared publications
Latest Publications
- 11 December 2002
- Published by Wiley in Clinical Transplantation
- Vol. 16, 40-44
Differential diagnosis of kidney transplant rejection and cyclosporin/tacrolimus nephropathy using urine cytology
- 11 December 2002
- Published by Wiley in Clinical Transplantation
- Vol. 16, 40-44
Differential diagnosis of kidney transplant rejection and cyclosporin/tacrolimus nephropathy using urine cytology
- 1 January 2002
- Vol. 13 (1) , 242-51
Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications.
The immunohistochemical detection of the complement degradation product C4d, a component of the classical complement pathway, offers a new and currently poorly defined tool in the evaluation of renal allograft biopsies. Our retrospective study aims at determining the diagnostic and clinical significance of C4d accumulation in kidney transplants, employing immunofluorescence microscopy. We analyzed 398 diagnostic allograft biopsies (n = 265 patients with 1 to 5 biopsies obtained 7 to 7165 d posttransplantation [tx]) and correlated the detection of C4d with 18 histologic changes, panel-reactive antibody titers, response to treatment, and outcome. One hundred twenty-five native kidney and baseline tx biopsies served as controls. Linear deposition of C4d along peritubular capillaries was only found in a subgroup (30%) of allografts post-tx, mainly during the early time-course (median, 38 d post-tx; range, 7 to 5646 d). There was no significant association with infections. C4d staining could change from negative to positive and vice versa within days to weeks. The accumulation of C4d was most tightly linked to a morphologic subtype of rejection, transplant glomerulitis (P < 0.0001). In addition, tubular MHC class II expression was correlated with C4d deposition (P < 0.0001). Both features are signs of "acute active rejection." In comparison with C4d-negative controls, 43% of C4d-positive patients showed increased (>10%) panel-reactive antibody titers (versus 19% in the negative group; P = 0.001). C4d positivity was frequently associated with higher serum creatinine levels at time of biopsy (compared with C4d-negative group; P < 0.01). More C4d-positive patients were treated with polyclonal antithymocyte globulins (ATG) or monoclonal anti-CD3 antibodies (OKT3) (P < 0.0001). Outcome did not significantly differ between C4d-positive and C4d-negative groups. In conclusion, the detection of C4d identifies a humoral alloresponse in a subgroup of kidney transplants, which is often associated with signs of cellular rejection, i.e. tx glomerulitis. Allograft dysfunction in C4d-positive rejection episodes is often more pronounced. We provide first evidence that C4d-positive rejection might benefit from intensive therapy, potentially preventing the previously reported high graft failure rate. In addition, we show that a subgroup of C4d-positive cases may not require any immediate therapeutic intervention. The presence of C4d is clinically relevant and should be reported in the histologic diagnosis.
- 1 January 2002
- Vol. 13 (1) , 242-51
Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications.
The immunohistochemical detection of the complement degradation product C4d, a component of the classical complement pathway, offers a new and currently poorly defined tool in the evaluation of renal allograft biopsies. Our retrospective study aims at determining the diagnostic and clinical significance of C4d accumulation in kidney transplants, employing immunofluorescence microscopy. We analyzed 398 diagnostic allograft biopsies (n = 265 patients with 1 to 5 biopsies obtained 7 to 7165 d posttransplantation [tx]) and correlated the detection of C4d with 18 histologic changes, panel-reactive antibody titers, response to treatment, and outcome. One hundred twenty-five native kidney and baseline tx biopsies served as controls. Linear deposition of C4d along peritubular capillaries was only found in a subgroup (30%) of allografts post-tx, mainly during the early time-course (median, 38 d post-tx; range, 7 to 5646 d). There was no significant association with infections. C4d staining could change from negative to positive and vice versa within days to weeks. The accumulation of C4d was most tightly linked to a morphologic subtype of rejection, transplant glomerulitis (P < 0.0001). In addition, tubular MHC class II expression was correlated with C4d deposition (P < 0.0001). Both features are signs of "acute active rejection." In comparison with C4d-negative controls, 43% of C4d-positive patients showed increased (>10%) panel-reactive antibody titers (versus 19% in the negative group; P = 0.001). C4d positivity was frequently associated with higher serum creatinine levels at time of biopsy (compared with C4d-negative group; P < 0.01). More C4d-positive patients were treated with polyclonal antithymocyte globulins (ATG) or monoclonal anti-CD3 antibodies (OKT3) (P < 0.0001). Outcome did not significantly differ between C4d-positive and C4d-negative groups. In conclusion, the detection of C4d identifies a humoral alloresponse in a subgroup of kidney transplants, which is often associated with signs of cellular rejection, i.e. tx glomerulitis. Allograft dysfunction in C4d-positive rejection episodes is often more pronounced. We provide first evidence that C4d-positive rejection might benefit from intensive therapy, potentially preventing the previously reported high graft failure rate. In addition, we show that a subgroup of C4d-positive cases may not require any immediate therapeutic intervention. The presence of C4d is clinically relevant and should be reported in the histologic diagnosis.
- 1 May 1999
- Vol. 10 (5) , 1080-9
Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease.
Polyomavirus (PV) exceptionally causes a morphologically manifest renal allograft infection. Five such cases were encountered in this study, and were followed between 40 and 330 d during persistent PV renal allograft infection. Transplant (Tx) control groups without PV graft infection were analyzed for comparison. Tissue and urine samples were evaluated by light microscopy, immunohistochemistry, electron microscopy, and PCR. The initial diagnosis of PV infection with the BK strain was made in biopsies 9+/-2 mo (mean +/- SD) post-Tx after prior rejection episodes and rescue therapy with tacrolimus. All subsequent biopsies showed persistent PV infection. Intranuclear viral inclusion bodies in epithelial cells along the entire nephron and the transitional cell layer were histologic hallmarks of infection. Affected tubular cells were enlarged and often necrotic. In two patients, small glomerular crescents were found. In 54% of biopsies, infection was associated with pronounced inflammation, which had features of cellular rejection. All patients were excreting PV-infected cells in the urine. PV infection was associated with 40% graft loss (2 of 5) and a serum creatinine of 484+/-326 micromol/L (mean +/- SD; 11 mo post-Tx). Tx control groups showed PV-infected cells in the urine in 5%. Control subjects had fewer rejection episodes (P<0.05) and stable graft function (P = 0.01). It is concluded that a manifest renal allograft infection with PV (BK strain) can persist in heavily immunosuppressed patients with recurrent rejection episodes. PV mainly affects tubular cells and causes necrosis, a major reason for functional deterioration. A biopsy is required for diagnosis. Urine cytology can serve as an adjunct diagnostic tool.
- 1 May 1999
- Vol. 10 (5) , 1080-9
Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease.
Polyomavirus (PV) exceptionally causes a morphologically manifest renal allograft infection. Five such cases were encountered in this study, and were followed between 40 and 330 d during persistent PV renal allograft infection. Transplant (Tx) control groups without PV graft infection were analyzed for comparison. Tissue and urine samples were evaluated by light microscopy, immunohistochemistry, electron microscopy, and PCR. The initial diagnosis of PV infection with the BK strain was made in biopsies 9+/-2 mo (mean +/- SD) post-Tx after prior rejection episodes and rescue therapy with tacrolimus. All subsequent biopsies showed persistent PV infection. Intranuclear viral inclusion bodies in epithelial cells along the entire nephron and the transitional cell layer were histologic hallmarks of infection. Affected tubular cells were enlarged and often necrotic. In two patients, small glomerular crescents were found. In 54% of biopsies, infection was associated with pronounced inflammation, which had features of cellular rejection. All patients were excreting PV-infected cells in the urine. PV infection was associated with 40% graft loss (2 of 5) and a serum creatinine of 484+/-326 micromol/L (mean +/- SD; 11 mo post-Tx). Tx control groups showed PV-infected cells in the urine in 5%. Control subjects had fewer rejection episodes (P<0.05) and stable graft function (P = 0.01). It is concluded that a manifest renal allograft infection with PV (BK strain) can persist in heavily immunosuppressed patients with recurrent rejection episodes. PV mainly affects tubular cells and causes necrosis, a major reason for functional deterioration. A biopsy is required for diagnosis. Urine cytology can serve as an adjunct diagnostic tool.
- 1 June 1998
- Vol. 49 (6) , 356-63
The side-effects of ciclosporine-A and tacrolimus.
Ciclosporine-A (CSA) has been in clinical use as an immunosuppressive drug in transplant recipients for over a decade. Unfortunately, CSA also has major side-effects (including nephrotoxic ones). In an attempt to find safer agents, tacrolimus (TAC) has been introduced recently. Despite major differences in the chemical structure, TAC and CSA seem to have many effects in common. This phenomenon can be explained by the inhibition of the calcineurin pathway characteristic for both drugs. The aim of our brief review was to compare personal observations regarding side-effects encountered under CSA or TAC therapy with data reported previously. We found that the profile of side-effects both under CSA and TAC was nearly identical. In particular, morphologic changes associated with toxic drug effects in the kidney were indistinguishable from one another, i.e. tubular lesions, arteriolopathy, HUS-like changes in glomeruli and vessels. The prevalence of defined nephrotoxic lesions was very similar. Some differences were found regarding the prevalence of clinical side effects. Hypertension, hypertrichosis and gingival hyperplasia were less pronounced in the TAC group and an elevated blood glucose level in the CSA group. We conclude that TAC and CSA are closely related immunosuppressive drugs with regard to adverse effects.
- 1 June 1998
- Vol. 49 (6) , 356-63
The side-effects of ciclosporine-A and tacrolimus.
Ciclosporine-A (CSA) has been in clinical use as an immunosuppressive drug in transplant recipients for over a decade. Unfortunately, CSA also has major side-effects (including nephrotoxic ones). In an attempt to find safer agents, tacrolimus (TAC) has been introduced recently. Despite major differences in the chemical structure, TAC and CSA seem to have many effects in common. This phenomenon can be explained by the inhibition of the calcineurin pathway characteristic for both drugs. The aim of our brief review was to compare personal observations regarding side-effects encountered under CSA or TAC therapy with data reported previously. We found that the profile of side-effects both under CSA and TAC was nearly identical. In particular, morphologic changes associated with toxic drug effects in the kidney were indistinguishable from one another, i.e. tubular lesions, arteriolopathy, HUS-like changes in glomeruli and vessels. The prevalence of defined nephrotoxic lesions was very similar. Some differences were found regarding the prevalence of clinical side effects. Hypertension, hypertrichosis and gingival hyperplasia were less pronounced in the TAC group and an elevated blood glucose level in the CSA group. We conclude that TAC and CSA are closely related immunosuppressive drugs with regard to adverse effects.
- 1 January 1996
- Vol. 80, 318-21
[Detection of herpes virus-like DNA in various forms of Kaposi's sarcoma but not in other mesenchymal tumors or inflammatory changes in skin].
Recently, herpes-virus like DNA sequences defining a new herpes virus termed human herpes virus 8 (HHV8), were detected in Kaposi's sarcoma of AIDS and non-AIDS patients. We describe the successful detection of HHV8 DNA in archival skin biopsies of the various forms of Kaposi's sarcoma. DNA was extracted from archival skin biopsies of Kaposi's sarcoma, other mesenchymal skin tumors and various inflammatory skin lesion of HIV seropositive and negative patients. The extracted DNA was analyzed for the presence of HHV8 DNA using a nested PCR assay. All samples were tested for the presence of appropriate DNA using a internal cellular control PCR-reaction. A total of 23 Kaposi's sarcoma were analyzed, including 12 of the endemic type, 9 HIV-associated and 2 transplant related. HHV8 DNA was detected by nested PCR in all forms of Kaposi's sarcoma. In contrast, no HHV8 DNA could be found in 17 mesenchymal, especially vascular skin tumors or in 7 biopsies with unspecific inflammatory skin lesions of HIV seropositive and negative patients. HHV8 DNA was present in all forms of Kaposi's sarcoma tested but not in other mesenchymal tumors or unspecific inflammatory lesions of the skin. This data support the idea of a strong association of HHV8 and Kaposi's sarcoma.
- 1 January 1996
- Vol. 80, 318-21
[Detection of herpes virus-like DNA in various forms of Kaposi's sarcoma but not in other mesenchymal tumors or inflammatory changes in skin].
Recently, herpes-virus like DNA sequences defining a new herpes virus termed human herpes virus 8 (HHV8), were detected in Kaposi's sarcoma of AIDS and non-AIDS patients. We describe the successful detection of HHV8 DNA in archival skin biopsies of the various forms of Kaposi's sarcoma. DNA was extracted from archival skin biopsies of Kaposi's sarcoma, other mesenchymal skin tumors and various inflammatory skin lesion of HIV seropositive and negative patients. The extracted DNA was analyzed for the presence of HHV8 DNA using a nested PCR assay. All samples were tested for the presence of appropriate DNA using a internal cellular control PCR-reaction. A total of 23 Kaposi's sarcoma were analyzed, including 12 of the endemic type, 9 HIV-associated and 2 transplant related. HHV8 DNA was detected by nested PCR in all forms of Kaposi's sarcoma. In contrast, no HHV8 DNA could be found in 17 mesenchymal, especially vascular skin tumors or in 7 biopsies with unspecific inflammatory skin lesions of HIV seropositive and negative patients. HHV8 DNA was present in all forms of Kaposi's sarcoma tested but not in other mesenchymal tumors or unspecific inflammatory lesions of the skin. This data support the idea of a strong association of HHV8 and Kaposi's sarcoma.
- 1 December 1995
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 10 (12) , 2368-2370
A patient with microhematuria and proteinuria: Do we still need electronmicroscopy?
- 1 December 1995
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 10 (12) , 2368-2370
A patient with microhematuria and proteinuria: Do we still need electronmicroscopy?
- 1 December 1995
- Vol. 52, S63-9
The differential diagnosis between rejection and cyclosporine toxicity.
- 1 December 1995
- Vol. 52, S63-9
The differential diagnosis between rejection and cyclosporine toxicity.
- 1 February 1995
- Vol. 27 (1) , 39-42
Renal transplant morphology after long-term therapy with cyclosporine.
- 1 February 1995
- Vol. 27 (1) , 39-42
Renal transplant morphology after long-term therapy with cyclosporine.
- 31 May 1994
- Published by Elsevier in Pathology - Research and Practice
- Vol. 190 (5) , 417-422
Immunoelectron Microscopy of Different Forms of Glomerulonephritis in Routine Biopsy Material
- 31 May 1994
- Published by Elsevier in Pathology - Research and Practice
- Vol. 190 (5) , 417-422
Immunoelectron Microscopy of Different Forms of Glomerulonephritis in Routine Biopsy Material
- 20 January 1994
- Vol. 114 (2) , 166-8
[Renal changes in liver diseases].
Renal disease occurs frequently along with diseases of the liver. In autopsy material of patients with liver cirrhosis, half of the patients have morphological signs of secondary type IgA nephropathy. In this paper we report on the renal changes observed in patients with diseases of the liver, such as hepatic glomerulosclerosis, secondary IgA nephropathy, glomerulonephritis with viral hepatitis, systemic disease with hepatitis (mixed cryoglobulinemia and polyarteritis nodosa) with renal affection, renal changes after liver transplantation and the hepatorenal syndrome. The morphological changes of the kidney are emphasized.
- 20 January 1994
- Vol. 114 (2) , 166-8
[Renal changes in liver diseases].
Renal disease occurs frequently along with diseases of the liver. In autopsy material of patients with liver cirrhosis, half of the patients have morphological signs of secondary type IgA nephropathy. In this paper we report on the renal changes observed in patients with diseases of the liver, such as hepatic glomerulosclerosis, secondary IgA nephropathy, glomerulonephritis with viral hepatitis, systemic disease with hepatitis (mixed cryoglobulinemia and polyarteritis nodosa) with renal affection, renal changes after liver transplantation and the hepatorenal syndrome. The morphological changes of the kidney are emphasized.